First Line Durvalumab in Patients With PD-L1 Positive, Advanced NSCLC With Performance Status 2 Unsuitable for Combination Chemotherapy. A Multicenter, Single-arm Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Sep 2019 Status changed from recruiting to suspended.
- 18 Oct 2018 Status changed from not yet recruiting to recruiting.
- 17 Aug 2018 New trial record